Royal Bank Of Canada Issues Pessimistic Forecast for Moderna (NASDAQ:MRNA) Stock Price

Moderna (NASDAQ:MRNA) had its price target reduced by stock analysts at Royal Bank Of Canada from $28.00 to $25.00 in a report issued on Friday, MarketBeat Ratings reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 5.40% from the stock’s previous close.

A number of other equities analysts have also weighed in on MRNA. Morgan Stanley upped their target price on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Citigroup decreased their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. Berenberg Bank set a $28.00 price objective on shares of Moderna in a research note on Monday, November 17th. Leerink Partners decreased their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. Finally, Bank of America lowered their target price on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $29.46.

Moderna Trading Up 6.1%

Shares of NASDAQ MRNA opened at $23.72 on Friday. The firm has a market capitalization of $9.27 billion, a P/E ratio of -2.94 and a beta of 2.02. The firm’s 50-day moving average price is $25.87 and its 200-day moving average price is $26.96. Moderna has a 1-year low of $22.28 and a 1-year high of $48.92.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period last year, the business posted $0.03 EPS. The firm’s revenue for the quarter was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna will post -9.61 EPS for the current year.

Institutional Investors Weigh In On Moderna

Several large investors have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Moderna by 4.1% during the first quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 452,713 shares of the company’s stock worth $12,834,000 after buying an additional 17,799 shares during the last quarter. John G Ullman & Associates Inc. grew its position in shares of Moderna by 45.1% during the 1st quarter. John G Ullman & Associates Inc. now owns 14,950 shares of the company’s stock valued at $424,000 after acquiring an additional 4,650 shares during the period. Cetera Investment Advisers increased its stake in shares of Moderna by 20.7% during the 1st quarter. Cetera Investment Advisers now owns 49,215 shares of the company’s stock worth $1,395,000 after purchasing an additional 8,432 shares during the last quarter. HB Wealth Management LLC bought a new stake in shares of Moderna in the 1st quarter worth approximately $225,000. Finally, Empirical Finance LLC raised its holdings in shares of Moderna by 7.3% in the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock worth $261,000 after purchasing an additional 624 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.